These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 22218276)

  • 1. Long-lasting treatment effect of rituximab in MuSK myasthenia.
    Díaz-Manera J; Martínez-Hernández E; Querol L; Klooster R; Rojas-García R; Suárez-Calvet X; Muñoz-Blanco JL; Mazia C; Straasheijm KR; Gallardo E; Juárez C; Verschuuren JJ; Illa I
    Neurology; 2012 Jan; 78(3):189-93. PubMed ID: 22218276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients.
    Illa I; Diaz-Manera J; Rojas-Garcia R; Pradas J; Rey A; Blesa R; Juarez C; Gallardo E
    J Neuroimmunol; 2008 Sep; 201-202():90-4. PubMed ID: 18653247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab in the treatment of MuSK antibody-positive myasthenia gravis.
    Stein B; Bird SJ
    J Clin Neuromuscul Dis; 2011 Mar; 12(3):163-4. PubMed ID: 21321497
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis.
    Marino M; Basile U; Spagni G; Napodano C; Iorio R; Gulli F; Todi L; Provenzano C; Bartoccioni E; Evoli A
    Front Immunol; 2020; 11():613. PubMed ID: 32431692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.
    Hehir MK; Hobson-Webb LD; Benatar M; Barnett C; Silvestri NJ; Howard JF; Howard D; Visser A; Crum BA; Nowak R; Beekman R; Kumar A; Ruzhansky K; Chen IA; Pulley MT; LaBoy SM; Fellman MA; Greene SM; Pasnoor M; Burns TM
    Neurology; 2017 Sep; 89(10):1069-1077. PubMed ID: 28801338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Maddison P; McConville J; Farrugia ME; Davies N; Rose M; Norwood F; Jungbluth H; Robb S; Hilton-Jones D
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):671-3. PubMed ID: 20392977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis.
    Kuntzer T; Carota A; Novy J; Cavassini M; Du Pasquier RA
    Neurology; 2011 Feb; 76(8):757-8. PubMed ID: 21339503
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients.
    Keung B; Robeson KR; DiCapua DB; Rosen JB; O'Connor KC; Goldstein JM; Nowak RJ
    J Neurol Neurosurg Psychiatry; 2013 Dec; 84(12):1407-9. PubMed ID: 23761915
    [No Abstract]   [Full Text] [Related]  

  • 9. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.
    Topakian R; Zimprich F; Iglseder S; Embacher N; Guger M; Stieglbauer K; Langenscheidt D; Rath J; Quasthoff S; Simschitz P; Wanschitz J; Windisch D; Müller P; Oel D; Schustereder G; Einsiedler S; Eggers C; Löscher W
    J Neurol; 2019 Mar; 266(3):699-706. PubMed ID: 30649616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longstanding and Refractory Anti-Muscle Specific Tyrosine Kinase Antibody-Associated Myasthenia Gravis (Anti-MuSK-MG) in a Child Successfully Treated with Rituximab.
    Weger S; Appendino JP; Clark IH
    J Binocul Vis Ocul Motil; 2019; 69(1):26-29. PubMed ID: 30811277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
    Evoli A; Tonali PA; Padua L; Monaco ML; Scuderi F; Batocchi AP; Marino M; Bartoccioni E
    Brain; 2003 Oct; 126(Pt 10):2304-11. PubMed ID: 12821509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MuSK-Ab positive myasthenia: not always grave.
    Zouvelou V; Stamboulis E; Skriapa L; Tzartos SJ
    J Neurol Sci; 2013 Aug; 331(1-2):150-1. PubMed ID: 23706725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody.
    Zhou Y; Yan C; Gu X; Zhou L; Lu J; Zhu W; Huan X; Luo S; Zhong H; Lin J; Lu J; Zhao C; Xi J
    Muscle Nerve; 2021 Jun; 63(6):824-830. PubMed ID: 33745138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in refractory MuSK antibody myasthenia gravis.
    Thakre M; Inshasi J; Marashi M
    J Neurol; 2007 Jul; 254(7):968-9. PubMed ID: 17468964
    [No Abstract]   [Full Text] [Related]  

  • 15. Rituximab in the management of refractory myasthenia gravis.
    Zebardast N; Patwa HS; Novella SP; Goldstein JM
    Muscle Nerve; 2010 Mar; 41(3):375-8. PubMed ID: 19852027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-MuSK myasthenia gravis presenting with purely ocular findings.
    Caress JB; Hunt CH; Batish SD
    Arch Neurol; 2005 Jun; 62(6):1002-3. PubMed ID: 15956173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serological Markers of Clinical Improvement in MuSK Myasthenia Gravis.
    Spagni G; Vincent A; Sun B; Falso S; Jacobson LW; Devenish S; Evoli A; Damato V
    Neurol Neuroimmunol Neuroinflamm; 2024 Nov; 11(6):e200313. PubMed ID: 39250722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effect of intravenous immunoglobulin on anti-MuSK antibody-positive myasthenia gravis.
    Shibata-Hamaguchi A; Samuraki M; Furui E; Iwasa K; Yoshikawa H; Hayashi S; Yamada M
    Acta Neurol Scand; 2007 Dec; 116(6):406-8. PubMed ID: 17986100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis.
    Deymeer F; Gungor-Tuncer O; Yilmaz V; Parman Y; Serdaroglu P; Ozdemir C; Vincent A; Saruhan-Direskeneli G
    Neurology; 2007 Feb; 68(8):609-11. PubMed ID: 17310034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.
    Farrugia ME; Robson MD; Clover L; Anslow P; Newsom-Davis J; Kennett R; Hilton-Jones D; Matthews PM; Vincent A
    Brain; 2006 Jun; 129(Pt 6):1481-92. PubMed ID: 16672291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.